ZX008 Expanded Access Protocol
NCT03780127 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2023-10-24
Summary
The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 clinical trials.
Conditions
Interventions
- DRUG
-
Fenfluramine Hydrochloride
ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.
Sponsors & Collaborators
-
Zogenix, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
NCT00409175 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Safety Study of NNZ-2566 in Pediatric Rett Syndrome
NCT02715115 ·Status: COMPLETED ·Phase: PHASE2
-
Neurophysiological and Acute Pharmacological Studies in FXS Patients
NCT02998151 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Dose-Finding Study of SC411 in Children With Sickle Cell Disease
NCT02973360 ·Status: UNKNOWN ·Phase: PHASE2
-
Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
NCT07119775 ·Status: AVAILABLE
-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
NCT06283212 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
NCT03802799 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
NCT05418049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07281079 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
NCT05485987 ·Status: COMPLETED ·Phase: PHASE2
-
An Open Label Extension Study in Subjects With Fragile X Syndrome
NCT01555333 ·Status: TERMINATED ·Phase: PHASE3
-
Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses
NCT00672022 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome
NCT03595371 ·Status: TERMINATED ·Phase: PHASE2
-
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
NCT01703533 ·Status: COMPLETED ·Phase: PHASE2
-
AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease
NCT03533673 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of Minocycline to Treat Children With Fragile X Syndrome
NCT01053156 ·Status: COMPLETED ·Phase: NA
-
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
NCT06332807 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
NCT03614663 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02217007 ·Status: WITHDRAWN ·Phase: PHASE2
-
Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)
NCT05149898 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Miglustat in Chinese NPC Patients
NCT03910621 ·Status: COMPLETED ·Phase: PHASE4
-
Sapropterin Expanded Access Program
NCT00484991 ·Status: APPROVED_FOR_MARKETING
-
Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease
NCT00351156 ·Status: COMPLETED
-
Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
NCT00688597 ·Status: TERMINATED ·Phase: PHASE2
-
VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease
NCT02898753 ·Status: TERMINATED ·Phase: PHASE1/PHASE2